Apollomics, Inc. (APLM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 0 | 0 | 1 | 0 | 9 | 9 | 13 |
| Operating profit | $m | -9 | -9 | ||||||
| Net profit | $m | -75 | -95 | -241 | -173 | -54 | -11 | -11 | - |
| EPS reported | $ | -7.57 | -7.57 | ||||||
| Operating cashflow per share | $ | -7.18 | -24.63 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -7.18 | -24.63 | ||||||
| Free cash flow | $m | -10 | -10 | ||||||
| Net debt | $m | -3 | -3 | ||||||
| Book value equity | $m | -3 | -3 | ||||||
| Book value per share | $ | -2.21 | -7.57 | ||||||
| Number of shares | m | 1.45 | 0.42 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -8.48 | -8.48 | ||||||
| P/S LTM | x | 3.18 | 3.18 | ||||||
| P/FCF LTM | x | -2.61 | -2.61 | ||||||
| EV/EBITDA LTM | x | -2.65 | -2.57 | ||||||
| EV/Sales LTM | x | 2.87 | 6.79 | ||||||
| Earnings Yield LTM | % | -40.48% | -94.50% | ||||||
| FCF Yield | % | -38.37% | -38.37% | ||||||
| Quality | |||||||||
| ROE | % | +343.13% | +288.40% | ||||||
| ROIC | % | -15.87% | -15.87% | ||||||
| Operating margin | % | -1.11% | -1.11% | ||||||
| Gross margin | % | +97.00% | +100.00% | ||||||
| FCF/Sales | % | -121.99% | -121.99% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +4192.9% | +4192.9% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -16.13 | -16.13 | ||||||
| Net Debt/EBITDA | x | 0.29 | 0.28 | ||||||
| EBIT/Net interest | x | -145.74 | -145.74 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 1.03 | 1.03 | ||||||
| Gross debt/equity | x | -0.20 | -0.20 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free